Gauss is the leader in computer vision in healthcare. Founded in 2011, Gauss’s mission is to digitally augment clinicians with software that radically improves diagnostic accuracy and leads to improved patient safety and clinical outcomes. Gauss’s flagship product, Triton, leverages computer vision to detect surgical and obstetric hemorrhage in real time and notifies clinicians who can enact timely intervention and treatment. Triton was granted De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014, as the first-ever computer vision software for surgical use, and several follow-on 510(k) clearances. Available on the iPhone, Triton has been widely adopted by health systems in the United States and is a recipient of the Apple Design Award, which recognizes the best in design, innovation and technology on Apple platforms.
For more information, visit www.gauss.com.
Founded in 2002, Cellex is a pioneer accelerating the era of decentralized medicine. Cellex’s suite of diagnostics products for combating infectious diseases is based upon innovative point-of-care (POC) platform technologies. On April 1, 2020, Cellex was the first company to receive an FDA Emergency Use Authorization for a COVID-19 antibody test. Its rapid tests have been in widespread use by several states in the U.S.A and across the globe through the COVID-19 pandemic.
To learn more, visit www.cellex.us.